Hybio Pharmaceutical and iCarbonX-Peptide Sign Joint Development Agreement for GLP-1R/GIPR/GCGR Triple Agonist Peptide Innovative Drug

On May 9, 2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and Shenzhen iCarbonX Intelligent Peptide Pharmaceutical Technology Co., Ltd. (referred to as "iCarbonX Intelligent Peptide") formally signed a joint development agreement for GLP-1R/GIPR/GCGR triple agonist peptide innovative drugs and held a grand signing ceremony. Tang Yangming, Director and Vice President of Hybio Pharmaceutical, and Zhan Wenhu, R&D Vice President of iCarbonX Intelligent Peptide, signed the agreement on behalf of both parties. Present at and witnessing this important moment were leaders from both sides, including Zeng Shaogui, Chairman and President of Hybio Pharmaceutical; Yang Di, Director, Vice President and Secretary of the Board of Hybio Pharmaceutical; Chen Jiantao, Manager of R&D and Innovation Department of Hybio Pharmaceutical; Wang Jun, Founder and Executive President of iCarbonX; Wang Minkun, Commercial President of iCarbonX; and Xiao Bin, Technical Vice President of iCarbonX Intelligent Peptide.

This signing builds on the Strategic Cooperation Framework Agreement signed by both parties in October 2024 and the fruitful cooperation achievements made in the early stage. To further advance the project, the two sides have successfully screened out GLP-1R/GIPR/GCGR triple agonists by fully leveraging the "silicon-based peptide chip" screening combined with "artificial intelligence" technology. It is agreed that the two parties will take the multi-target peptide innovative drug project as the starting point, focus on the joint development of peptide innovative drugs, and commit to solutions for metabolic diseases such as weight loss and blood sugar reduction. The Peptide Drugs developed through this cooperation will have a variety of administration formulations, including but not limited to injections and oral preparations, which will be widely used in the treatment of metabolic diseases such as weight management.

Mr. Zeng Shaogui, Founder, Chairman and President of Hybio Pharmaceutical, stated: "This cooperation represents a key step in Hybio Pharmaceutical's advancement of the 'combination of innovation and imitation' strategy. The collaboration between Hybio Pharmaceutical and iCarbonX Intelligent Peptide has achieved full-chain coverage from R&D to production, and from technology to market. Building on the Strategic Cooperation Framework Agreement signed last October, we have joined hands with iCarbonX Intelligent Peptide to deeply integrate 'silicon-based peptide chip' screening, combined with 'artificial intelligence' algorithms, into peptide innovative drug R&D, which has effectively improved drug R&D efficiency. Going forward, we will accelerate the global follow-up development of this drug, striving to make it benefit a wide range of patients at an early date."

Mr. Wang Jun, Founder and Executive President of iCarbonX as well as Chairman of iCarbonX Intelligent Peptide, also stated: "The new-generation silicon-based peptide chip launched by iCarbonX, combined with AI drug screening technology, is reshaping the future landscape of drug research and development. The successful collaboration with Hybio Pharmaceutical this time fully demonstrates the powerful efficacy of iCarbonX's technology platform – leveraging AI models trained on big data generated by silicon-based peptide chips – in multi-target drug molecule screening, optimization of peptide and antibody drug design. The development of AI-driven pharmaceuticals has just begun, and the cooperation between Hybio Pharmaceutical and iCarbonX Intelligent Peptide is also in its early stages. We look forward to, through continuous technological iteration and integration of advantageous resources, jointly creating a new paradigm of 'silicon-based peptide chip' screening combined with 'artificial intelligence' technology and peptide innovative drug development. It is believed that the integration of iCarbonX's technology platform and AI models with Hybio Pharmaceutical's capabilities in production quality, registration and declaration, and global integration will spawn more cooperation opportunities and bring innovative breakthroughs to the pharmaceutical industry."

Hybio Pharmaceutical has established multi-dimensional technological barriers in pharmaceutical research by relying on its complete and efficient industrialization technology platform. The company focuses on innovation in formulation processes, applying cutting-edge technologies to enhance drug stability; precisely controls drug quality through research on key quality attributes such as impurity profile analysis; and at the same time, achieves cost reduction and efficiency improvement in the industrialization process, forming an efficient conversion system from compound research to commercial production. In the future, the company will continue to strengthen its innovation capabilities across the entire industry chain, accelerate the transformation of scientific research achievements into clinical value, and fulfill its corporate mission of "guarding life and health".

About Hybio Pharmaceutical
Hybio Pharmaceutical is a national high-tech enterprise specializing in the integrated R&D, production, and sales of peptide and oligonucleotide drugs. It boasts internationally advanced comprehensive capabilities in the industrialization and marketing of peptide and oligonucleotide drugs. The company is committed to providing more effective treatment options for patients and driving the development of the pharmaceutical industry through technological innovation and high-quality products.

About iCarbonX Intelligent Peptide
As a pharmaceutical platform under iCarbonX, iCarbonX Intelligent Peptide leverages its independently developed silicon-based peptide chip technology and AI Drug Discovery & optimization models trained on high-throughput data. It is dedicated to empowering biopharmaceutical and technology companies to accelerate the development of macromolecular new drugs, enhance drug bioactivity, stability, and targeting, and meet clinical translation needs. With its unique technologies and innovative concepts, the company brings new vitality and possibilities to the field of drug R&D, facilitating more efficient drug development in the industry.